A Phase I, Randomized, Open-label, Multi-center, Multiple Dose Study to Investigate the Pharmacokinetics and Pharmacodynamics of RO5185426 Administered as 240 mg Tablets to Previously Treated BRAF V600E Positive Metastatic Melanoma Patients

Inclusion Criteria:

- adult patients, >/=18 years of age

- histologically confirmed metastatic melanoma, stage IIIc or IV (AJCC)

- failure of at least one prior standard of care regimen

- positive for BRAF V600E mutation (by Roche CoDx BRAF mutation assay)

- ECOG performance status 0 or 1

- adequate hematologic, renal and liver function

Exclusion Criteria:

- active CNS lesions on CT/MRI within 28 days prior to enrollment

- history of spinal cord compression o carcinomatous meningitis

- anticipated or ongoing anti-cancer therapies other than those administered in this
study

- previous treatment with BRAF inhibitor (sorafenib allowed) or MEK inhibitor

- severe cardiovascular disease within 6 months prior to study

- previous malignancy within the past 5 years except for basal or squamous cell
carcinoma of the skin, melanoma in-situ and carcinoma in-situ of the cervix